Ascletis to Post ASC48 and ASC37 Obesity Data at ObesityWeek 2026
Ascletis will present preclinical ASC48 and ASC37 posters at ObesityWeek 2026, including a company-attributed claim of a 6-fold longer half-life than retatrutide in NHP.
Piramal to Acquire Hemmo Pharmaceuticals, Adding Peptide API Manufacturing to CDMO Arm
Piramal Pharma Limited acquires Hemmo Pharmaceuticals for INR 775 crores, marking its CDMO arm’s entry into peptide API manufacturing. The deal adds 30+ APIs and a GMP-certified facility.